Category: Market News

Inspiration Healthcare (LSE:IHC) reported a robust performance for FY26, with revenue increasing 24% to £47.5 million, supported by strong demand for its SLE neonatal ventilation products. Sales of SLE products climbed 56% during the year, helping to improve gross margins and drive adjusted EBITDA to £2.8 million.

The group also strengthened its balance sheet through tighter working capital management, generating £7.5 million in operating cash flow and reducing net debt by 39% to £5.1 million. Operational improvements boosted manufacturing efficiency and contributed to a one-third reduction in inventory levels.

Strong Trading Supported by Key Contracts

During the year, Inspiration Healthcare completed a significant one-off export contract worth £9.5 million and delivered 10% underlying growth across the SLE business. The company also secured a multi-year purchasing agreement for its Airon division with a major U.S. healthcare provider, further expanding its presence in a key market.

Management highlighted the benefits of ongoing operational improvements, which have increased production capacity while supporting better inventory control and cash generation.

Strategic Shift Towards Core Neonatal Technologies

Following the year-end, the company agreed to transfer its infusion business to Micrel, a move designed to increase focus on its higher-priority neonatal technology operations. The disposal is expected to streamline the business and allow management to concentrate resources on areas with stronger long-term growth potential.

Despite the planned exit from lower-margin infusion distribution activities, the board expressed confidence in achieving market expectations for FY27 and remains optimistic about prospects heading into FY28.

Focused Platform for Future Growth

The company believes its combination of neonatal ventilation expertise, international distribution capabilities and growing U.S. presence provides a solid foundation for future expansion. Management expects continued investment in core technologies and operational efficiency to support further growth and profitability improvements.

Market Considerations

The company’s outlook continues to be influenced by concerns around financial performance, including historical losses, margin pressure, leverage and cash flow challenges. However, positive technical indicators, including a strong share price trend and favourable momentum signals, provide some support. Valuation remains constrained by negative earnings metrics and the absence of a positive price-to-earnings ratio.

More About Inspiration Healthcare

Inspiration Healthcare Group is a UK-based medical technology company focused on products used in neonatal intensive care. Its portfolio includes neonatal ventilators, respiratory support systems and single-use medical consumables designed to support premature and critically ill newborns.

The company markets both proprietary and distributed products directly to healthcare providers in the UK and Ireland, while also serving international markets through a distributor network spanning more than 75 countries. Its operations include SLE, a specialist in neonatal ventilation; Airon, a U.S.-based pneumatic ventilation business; and its UK and Ireland medical technology distribution division.

Gelion (LSE:GELN) has entered into an exclusive worldwide commercial licensing agreement with Max-Planck-Innovation GmbH covering nano-encapsulated sulfur cathode technology and advanced nano-confined anode materials. The agreement brings together both existing and future intellectual property generated through Gelion’s collaboration with the Max Planck Institute of Colloids and Interfaces.

Structured around milestone payments and royalty arrangements, the deal strengthens Gelion’s intellectual property portfolio and provides greater certainty as the company advances its sulfur battery technologies towards commercial deployment.

Strengthened Intellectual Property Platform

The licence gives Gelion exclusive access to key technologies that underpin recent advances in sulfur battery performance, including improvements in energy density, power delivery, operating temperature range and cycle life.

Management believes the agreement reduces commercialisation risk by securing long-term rights to critical innovations while creating a clearer route for integrating these developments into the company’s next-generation battery products. The strengthened IP position is also expected to support discussions with industrial partners and future commercial opportunities.

Accelerating the Path to Market

By securing exclusive rights to the technology, Gelion aims to move more rapidly from research and development into commercial execution. The company believes the agreement will help accelerate customer qualification programmes and collaboration efforts with Tier One industrial partners seeking advanced energy storage solutions.

The long-term access to breakthrough sulfur chemistry is expected to support the rollout of Gelion’s NES™ materials platform and enhance its ability to compete within fast-growing sustainable energy storage markets.

Building a Commercial Framework for Growth

The company views the agreement as an important step in transforming its scientific progress into scalable commercial products. As demand for advanced battery technologies increases across electric mobility, aviation and grid storage applications, Gelion believes its sulfur-based technologies offer a differentiated solution capable of leveraging existing battery manufacturing infrastructure.

Market Considerations

Gelion’s outlook continues to be influenced by ongoing losses, cash burn and a valuation profile constrained by negative earnings. However, these factors are partially offset by improving technical indicators, including a share price trading above key moving averages and positive momentum signals. Recent corporate updates have also highlighted progress on both technical and commercial milestones, alongside an improved EBITDA loss position, although execution and timing risks remain.

More About Gelion PLC

Gelion plc is a battery technology company focused on developing sulfur-based energy storage solutions for the clean energy transition. Its flagship Nano-Encapsulated Sulfur (NES™) technology is designed as a drop-in cathode material for lithium-sulfur and sodium-sulfur batteries, enabling compatibility with existing gigafactory infrastructure. The technology is being developed for applications including electric vehicles, e-aviation and large-scale grid energy storage.

Galileo Resources (LSE:GLR) has entered into an agreement to sell its wholly owned subsidiary, Virgo Business Solutions, to Metal Capital, a subsidiary of Sandfire Resources. Virgo holds two prospecting licences within Botswana’s Kalahari Copper Belt, and the transaction will deliver an upfront cash payment of US$3 million to Galileo.

The company intends to use the proceeds to support the advancement of its key projects in Zambia and Zimbabwe, reflecting its strategy of concentrating both capital and management attention on its core exploration regions.

Transaction Retains Significant Exploration Upside

In addition to the initial consideration, the agreement includes a contingent success payment ranging from US$20 million to US$80 million. The additional payment would become payable if future exploration activities result in the definition of a qualifying ore reserve containing at least 400,000 tonnes of copper.

While no mineral resource has yet been established on the licences and the contingent payment is not guaranteed, the structure allows Galileo to maintain exposure to the potential value of any major discovery without committing further exploration capital.

Major Exploration Commitment From Buyer

As part of the transaction, Metal Capital has committed to spend US$4.5 million on exploration activities across the licences. The programme is expected to include extensive drilling, with significant work scheduled to be completed by the end of 2026.

Galileo expects the disposal to generate a profit and strengthen its financial position, while simultaneously allowing the company to focus on developing its existing portfolio in southern Africa.

Strategic Focus on Core Assets

The sale represents another step in Galileo’s approach of monetising non-core assets and redeploying capital into projects where it sees the greatest opportunity for value creation. Management believes the transaction provides immediate funding while preserving the possibility of substantial future returns linked to exploration success.

Market Considerations

The company’s outlook continues to be influenced by a lack of revenue, recurring operating losses and negative free cash flow, although its debt-free balance sheet provides an important offsetting strength. Technical indicators are generally neutral to modestly positive, while valuation remains difficult to assess given negative earnings and the absence of a dividend yield.

More About Galileo Resources

Galileo Resources is a mineral exploration and development company focused primarily on copper and other base metals in southern Africa. The group’s main activities are centred on exploration projects in Zambia and Zimbabwe, while it continues to evaluate opportunities to unlock value from non-core assets and redirect capital towards priority growth areas.

Poolbeg Pharma (LSE:POLB) has received a decision to grant a European patent covering the use of POLB 001 for the prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The patent protection extends to p38 MAPK inhibitors across key member states of the European Patent Organisation, representing a significant addition to the company’s intellectual property portfolio.

The development follows recent patent grants in Australia and Canada and further strengthens Poolbeg’s protection in major pharmaceutical markets worldwide.

Intellectual Property Position Strengthened

The newly granted patent enhances the company’s competitive position as it progresses POLB 001 through clinical development. Poolbeg believes the expanded intellectual property coverage increases the strategic and commercial value of the programme while providing greater protection for future development and licensing opportunities.

Management has highlighted the importance of a robust patent estate in supporting the long-term potential of POLB 001, particularly as interest in therapies designed to improve the safety of cancer immunotherapies continues to grow.

Clinical Milestones on the Horizon

Poolbeg is continuing to advance POLB 001 through its development pathway, with interim data from the ongoing TOPICAL trial expected later this summer. The company believes the combination of clinical progress and strengthened patent protection enhances the attractiveness of the asset to potential pharmaceutical partners.

The upcoming trial results are expected to provide further insight into the potential role of POLB 001 in reducing the risk of Cytokine Release Syndrome, a serious complication associated with certain cancer immunotherapy treatments.

Market Considerations

The company’s outlook continues to be influenced by its pre-revenue status, ongoing losses, cash burn and equity erosion. However, recent regulatory and clinical progress, together with upcoming data readouts, provide potential catalysts for investor interest. Technical indicators suggest the shares remain in a strong upward trend, although overbought conditions may increase the risk of near-term volatility. Valuation metrics remain constrained by the absence of earnings and dividend payments.

More About Poolbeg Pharma Ltd.

Poolbeg Pharma is a clinical-stage biopharmaceutical company focused on advancing therapies that improve outcomes in cancer immunotherapy. Its lead programme, POLB 001, is being developed to prevent Cytokine Release Syndrome, with the goal of making cancer immunotherapies safer and more accessible. The company is also developing an oral GLP-1 treatment for obesity, targeting a large and rapidly growing global market.

Gana Media Group (LSE:GANA) has completed a £750,000 fundraising before expenses through a placing and subscription of 375,000,000 new ordinary shares at 0.2 pence per share, representing a slight premium to the company’s recent AIM closing price. The fundraising also includes warrants exercisable at 0.4 pence, with directors participating in the transaction.

Following the issue of the new shares, Gana’s total issued share capital will increase to approximately 18.1 billion shares. Outstanding warrants and options will represent around 16% of the enlarged share capital.

Capital Targeted at Estadio Gana Growth Initiatives

The proceeds will be used to accelerate growth plans centred on Estadio Gana, the company’s online casino and sportsbook platform in Mexico. Management reported strong increases in both customer registrations and wagering activity during the second quarter, reinforcing confidence in the platform’s growth trajectory.

The company believes the additional funding will allow it to build on this momentum and strengthen its position ahead of the upcoming World Cup period. Management expects the investment to support further market penetration and enhance the brand’s presence within the expanding Latin American online betting and entertainment sector.

Focus on Scaling Operations

Gana sees the fundraising as an opportunity to invest in customer acquisition, platform development and broader commercial initiatives as it seeks to expand its footprint in one of the region’s fastest-growing digital wagering markets.

While recent operational trends have been encouraging, the company continues to focus on converting growth into sustainable financial performance as it scales its sportsbook and gaming operations.

Market Considerations

The company’s outlook remains constrained by continuing operating losses and negative free cash flow, despite a recovery in revenue during FY2025 and strong gross margins. Technical indicators continue to reflect a prolonged downward trend, with the share price trading below key moving averages and momentum signals remaining weak. Valuation metrics also provide limited support due to the absence of positive earnings and dividend income.

More About Gana Media Group

Gana Media Group is an AIM-listed content and data intelligence business focused on building an integrated sports, media and entertainment platform across Latin America. The company’s portfolio includes Estadio Gana, a licensed Mexican online casino and sportsbook designed to capture growing demand for digital betting and gaming services in the region.

Pri0r1ty Intelligence Group (LSE:PR1) has secured a 12-month agreement between its Halfspace division and the Sport & Recreation Alliance, under which Halfspace will serve as the organisation’s official AI partner. The partnership includes the launch of the SportTower.ai platform, which will be made available to almost 300 sports and recreation bodies across the UK, representing an estimated 15,000 users.

The agreement marks the first commercial deployment of SportTower.ai, providing Alliance members with access to Pri0r1ty’s artificial intelligence and data analytics capabilities. The platform is designed to help organisations strengthen community engagement, improve decision-making and identify new revenue opportunities. For Pri0r1ty, the partnership also establishes a scalable framework that can be replicated across other industries and strategic alliances.

AI Platform Designed for Sector-Wide Adoption

Developed using Pri0r1ty’s existing AI technology stack, SportTower.ai includes a range of tools such as Advisor, Fan Sonar, Vox and Compass ID. The platform also delivers industry trend analysis and enables organisations to build AI-driven systems using their own datasets within a GDPR-compliant environment.

Halfspace expects to generate recurring revenues as Alliance members adopt and subscribe to elements of the product suite. The company believes the partnership strengthens its position within the sports sector while creating opportunities to expand its reach through additional collaborations and deployments in the months ahead.

Expanding Presence Across Key Markets

The launch represents another step in Pri0r1ty’s strategy to broaden the adoption of its AI solutions and data-driven services. By working with a large network of sports and recreation organisations, the company aims to demonstrate the practical benefits of its technology while establishing a repeatable model for future growth.

More About Pri0r1ty Intelligence Group PLC

Pri0r1ty Intelligence Group PLC is a UK-listed provider of data, artificial intelligence and marketing services focused on helping organisations improve engagement and growth. The business operates through three divisions: Halfspace, which specialises in data-led marketing and growth solutions for the sports industry; Pri0r1ty, an AI software and consultancy platform serving SMEs; and Metr1c, which delivers brand partnership and growth solutions for the entertainment sector.

U.S. equity futures pointed to a strong opening on Monday as investors reacted positively to reports that the United States and Iran have reached an agreement to end a conflict that has lasted for more than three months.

The development boosted risk appetite across financial markets, with traders focusing on the potential benefits of lower energy prices and reduced inflationary pressures.

Trump Signals End to Hostilities

President Donald Trump announced on Truth Social that a deal with Iran is “now complete” and authorized the “toll free opening” of the Strait or Hormuz along with the immediate removal of the U.S. blockade of Iranian ports.

Trump later explained that the waterway would reopen following the formal signing of the agreement on Friday, allowing time for mine-clearing operations.

According to reports, the agreement extends the ceasefire between Washington and Tehran for 60 days, creating an opportunity for negotiations regarding Iran’s nuclear programme and its stockpile of highly enriched uranium.

Oil Drops Sharply Following the Announcement

Crude prices fell more than 5% after the news, easing fears that elevated energy costs could continue feeding inflation.

“Prior to the deal, investors had become increasingly concerned that higher energy costs would feed into broader inflation pressures and potentially force policymakers into additional tightening,” said Daniela Hathorn, Senior Market Analyst at Capital.com.

“The sharp decline in oil prices does not eliminate inflation risks altogether, but it does reduce some of the urgency surrounding them,” she added. “That is particularly relevant this week as the Federal Reserve meets for the first time under new Chair Kevin Warsh.”

Stocks Extend Last Week’s Rally

The latest gains build on the momentum generated at the end of last week.

On Friday, the Dow Jones Industrial Average rose 0.7% to 51,202.26, while the S&P 500 gained 0.5% to 7,431.46. The Nasdaq added 0.3% to finish at 25,888.84.

All three major benchmarks advanced 0.7% for the week.

Uncertainty Remains Around Final Terms

Despite the positive market reaction, questions remain regarding the final structure of the agreement.

Trump, who last week called off a planned strike on Iran and indicated that a peace deal was close, later challenged reports emerging from Tehran.

In a Truth Social post on Monday, he said details released by Iran had “NOTHING to do with the terms that were agreed to, in writing.”

He also described the Iranians as “very dishonorable people to deal with,” adding, “With them, there is no such thing as dealing in good faith.”

Reports suggest the proposed memorandum would reopen the Strait of Hormuz without tolls and provide sanctions relief tied to compliance measures.

The arrangement would also maintain a 60-day ceasefire, including in Lebanon, while broader nuclear negotiations take place.

Bloomberg reported that the agreement could be signed during next week’s G7 summit.

Further support for investor sentiment came after Pakistani Prime Minister Shehbaz Sharif stated on X that a “final, agreed upon text of the peace deal has been reached.”

SpaceX Continues to Attract Investor Interest

Investors also kept a close watch on SpaceX (NASDAQ:SPCX), which completed the largest IPO ever on Friday.

The company surged 19.3% during its first day of trading, helping fuel enthusiasm for high-growth technology and innovation-focused stocks.

Gold, Airlines and Tech Stocks Outperform

Gold-related shares climbed as bullion prices strengthened, driving the NYSE Arca Gold Bugs Index up 3.1%.

Airline stocks also benefited from the sharp drop in fuel prices, with the NYSE Arca Airline Index gaining 2.8%.

Meanwhile, financial stocks, semiconductor companies and computer hardware firms posted solid gains, while biotechnology and utility shares lagged behind the broader market.

SpaceX shares closed 19% above their IPO price of $135 on the first day of trading, and the momentum continued into Monday’s pre-market session, with the stock gaining a further 5%. 

So, the skeptics who predicted the IPO would fail were wrong? 

Time will tell, but for now, the rally seems to be driven less by fundamentals and more by hype around the company and investors hoping to capitalize on the idea that SpaceX stock will soon be added to major indices. For instance, although the S&P 500 has stuck to its standard criteria, the Nasdaq has revised its index inclusion rules to speed up the process, which could end up forcing large passive funds to buy the stock.

At the same time, news that the United States and Iran may be close to reaching an agreement could have contributed to the momentum.

The problem with the latter is that reopening the Strait of Hormuz would not immediately lower global inflation. Moreover, parts of the proposed agreement may be difficult to implement, and even if a memorandum is signed, the U.S. and Iran would still need to agree on the nuclear program and other unresolved issues. Thus, a deal reached this week would not necessarily end the conflict.

As for SpaceX itself, even before the IPO, Morningstar assigned a fair value estimate of just $63 per share.

Today, SpaceX’s market capitalization exceeds that of Taiwan Semiconductor Manufacturing Company, despite the fact that, as of Q1 2026, TSMC reported earnings per share of $3.49 on revenue of $35.9 billion, surpassing analyst expectations, whereas SpaceX had $4.7 billion in revenue in the first quarter of 2026 but a net loss of $4.3 billion.

This does not necessarily mean the stock cannot continue rising in the short term; however, if the hype fades and investor sentiment shifts, the correction could be sharp, and if that occurs after the stock has been included in major indices, the consequences may extend beyond SpaceX itself.